Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome

Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics to the heart, announced today that the U.S. Food and Drug Administration ...
Nasdaq

FDA Accepts DrugSorb-ATR De Novo Application To Reduce the Severity of CABG-Related Bleeding Due to Ticagrelor and Initiates Substantive Review

PRINCETON, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery ...
Business Wire

Azitra, Inc. Announces Positive Preclinical Data of ATR-12 and Clinical Design in Netherton Syndrome Presented at the ASGCT Annual Meeting

BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced ...
Morningstar

CytoSorbents to Appeal Canadian Rejection of License Application for DrugSorb-ATR

CytoSorbents plans to ask Canadian health authorities to reconsider rejecting the company's license application for DrugSorb-ATR, an investigational device designed to reduce the severity of bleeding ...
Nasdaq

CytoSorbents Issues Regulatory Update On DrugSorb-ATR; Plans To File New De Novo Application

(RTTNews) - CytoSorbents (CTSO) issued a regulatory update on DrugSorb-ATR. The company has decided to not file a final appeal with CDRH because of positive FDA upper management feedback for a ...
ascopubs.org

Pathway for the Development of ATR Inhibitors in Pediatric Malignancies: An ACCELERATE Multistakeholder Analysis

Olaparib in Patients With Solid Tumors With ATM Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study High levels of DNA replication stress and defects in the ...